The Rainbow Coral Corp. is working closely with Nano3D Biosciences to develop and market the BiO Assay, the world's first commercially available 3D bioprinting system designed for high throughput and high-content drug screening.
RBCC says the automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures.
The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible.
The Bio Assay package runs $1,699. It is capable of automatically analyzing hundreds of images in minutes with N3D software to provide data like a dose response model.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies like Biogen Idec Inc., Abbott Laboratories and Amgen Inc. In 2012, Rainbow Biosciences acquired an equity interest in N3D.
The company is hoping to stake a claim in the booming 3D printing market.
Earlier this month, a Credit Suisse research team revised the firm's 2016 projection for the 3D printing market up 357 percent, from $175 million to $800 million. In four years, Wohlers Associates believes that the sale of 3D printing products and services will approach $6 billion world wide, and $10.8 billion by 2021.
Overlooked market opportunities for emerging 3D printing technology are responsible for the revised projections. One of those overlooked opportunities is 3D bioprinting, which involves printing cell-loaded replicas of human tissues for the purposes of drug testing and regenerative medicine.